Intrahepatic cholestasis in acute viral hepatitis: a double-blind trial with dihydroxydibutylether in comparison with placebo.
The authors studied the effectiveness of a choleretic drug, dihydroxydibutylether (DHBE), 900 mg daily, in patients with acute viral hepatitis and intrahepatic cholestasis. The four-week, double-blind and placebo-controlled trial showed a more rapid return to normal bilirubin and fasting and post-prandial biliary acid values and plasma transaminases levels in the DHBE-treated group of patients.
Marchettini
G
G
Corsini
P
P
Massimini
G
G
D000293:Adolescent; D000328:Adult; D000368:Aged; D001647:Bile Acids and Salts / Q000032:analysis; D002756:Cholagogues and Choleretics / Q000627:therapeutic use*; D002780:Cholestasis, Intrahepatic / Q000150:complications / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004987:Ethers / Q000627:therapeutic use*; D005260:Female; D006525:Hepatitis, Viral, Human / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged
D001647:Bile Acids and Salts; D002756:Cholagogues and Choleretics; D004987:Ethers; C000987:4,4'-oxydi-2-butanol